Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Cancer patients receiving treatment may mount inadequate immune response to COVID-19 vaccination

by Medical Finance
in Coronavirus
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies
9
SHARES
105
VIEWS
Share on FacebookShare on Twitter

A study by researchers at Mayo Clinic Cancer Center has found that patients with cancer who receive chemotherapy – and some targeted therapies, such as CDK4/6 inhibitors and therapies targeted at B cells – may mount an inadequate immune response to COVID-19 vaccination. The findings are published in Mayo Clinic Proceedings: Innovation, Quality & Outcomes.

It is important for patients with cancer who are receiving chemotherapy to receive a COVID-19 vaccine.”


Saranya Chumsri, M.D., Mayo Clinic hematologist and oncologist, and author of the paper

Dr. Chumsri says this advice also applies to patients with cancer who are taking a CDK 4/6 inhibitors. These inhibitors are a newer class of medicines used to treat hormone-receptor-positive and HER2-negative breast cancers.

Dr. Chumsri says that while CDK 4/6 inhibitors are not conventionally considered to be as immunosuppressive as chemotherapy, her research on patients with breast cancer who take these drugs found that they exhibited less optimal neutralizing antibody activity. Dr. Chumsri recommends that antibody levels be tested in these patients after vaccination, and they should consider receiving booster vaccinations for COVID-19.

Dr. Chumsri anticipates having additional data later this year regarding broader immune responses to COVID-19 vaccinations, including cellular and antibody responses in patients receiving chemotherapy and targeted therapies with booster vaccinations.

Source:

Journal reference:

Chumsri, S., et al. (2021) Humoral Responses after SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clinic Proceedings Innovations Quality & Outcomes. doi.org/10.1016/j.mayocpiqo.2021.12.004.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Covariant Fitness Clusters Reveal Structural Evolution of SARS-CoV-2 Polymerase Across the Human Population. Image Credit: Naeblys/Shutterstock

Analyzing the evolution of SARS-CoV-2 RNA polymerase in humans

by Medical Finance
May 20, 2022
0

A recent work posted by researchers to the bioRxiv* preprint server investigated the evolutionary aspects of severe acute respiratory syndrome...

Study: A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron. Image Credit: Lightspring/Shutterstock

New method for monitoring circulating SARS-CoV-2 variants and detecting new ones

by Medical Finance
May 20, 2022
0

After more than two years of the coronavirus disease (COVID-19) pandemic, there is still a constant threat of evolving strains...

Study: Structural and functional impact by SARS-CoV-2 Omicron spike mutations. Image Credit: MattLphotography/Shutterstock

Omicron variant spike protein shows significantly weaker membrane fusion activity than other variants

by Medical Finance
May 20, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has shown significantly higher transmission rates than other variants, despite...

Study: Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network. Image Credit: UGREEN S / Shutterstock.com

The connection between severe COVID-19 and diabetes

by Medical Finance
May 20, 2022
0

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the coronavirus disease 2019 (COVID-19) has nearly spread to every...

Study: Development of the one-step qualitative RT-PCR assay to detect SARS-CoV-2 Omicron (B.1.1.529) variant in respiratory specimens. Image Credit: anyaivanova/Shutterstock

Single-step RT-PCR for SARS-CoV-2 Omicron variant detection in respiratory samples

by Medical Finance
May 20, 2022
0

A new preprint describes a single-step molecular diagnostic test for the presence of severe acute respiratory syndrome coronavirus 2...

Study: Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. Image Credit: BaLL LunLa/Shutterstock

Comparing the Moderna and Pfizer-Biontech vaccines against SARS-CoV-2 infection

by Medical Finance
May 20, 2022
0

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed to combat the ongoing coronavirus disease 2019...

Next Post
TetraScience announces 300% ARR growth and 2021 achievements; prepares for next phase of growth

Origin, evolution and ecological relationships of yeasts

Study: SARS-CoV-2 Omicron-specific mRNA vaccine induces potent and broad antibody responses in vivo. Image Credit: angellodeco / Shutterstock.com

Researchers develop novel anti-SARS-CoV-2 Omicron vaccine candidate

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Homogeneity of sample distribution compared between contact pin spotter (left) and Arrayjet printer (right).
    Cost-effective and reproducible cell-free arrays
  • Study: Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients. Image Credit: Viacheslav Lopatin/Shutterstock
    Evaluating immune protection after third and fourth doses of homologous and heterologous SARS-CoV-2 vaccines among kidney transplant recipients
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply